Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market Intelligence.
Investors waiting to find out what Gilead Sciences would do with the tens of billions of dollars in its balance sheet were rewarded when the company announced it will be acquiring Kite Pharma (NASDAQ: KITE) in a deal valued at nearly $12 billion in cash.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Gilead Sciences Inc Stock
€77.06
0.640%
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Gilead Sciences Inc.
As a result the target price of 85 € shows a slightly positive potential of 10.3% compared to the current price of 77.06 € for Gilead Sciences Inc.
